 PAVmed Inc. Nasdaq: PAVM, PAVMZ the Company or PAVmed, a highly differentiated, multiproduct medical device company, today announced that the Companys majority owned subsidiary, Lucid Diagnostics Inc. Lucid, has received Breakthrough Device designation from the U.S. Food and Drug Administration FDA for its EsoGuardTM Esophageal DNA Test on esophageal samples collected using its EsoCheckTM Cell Collection Device in a prevalent well-defined group of patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease GERD. EsoGuards FDA Breakthrough Device designation represents a major milestone for PAVmed and Lucid, said Lishan Aklog, M.D., PAVmeds Chairman and Chief Executive Officer and Lucids Executive Chairman. 